Paratek Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$8.1Mgeneral payments (2019-2025)
$1,376research payments (2019-2025)
31,132clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Andrew Dold | Dacula, GA | Infectious Disease | $606,902.54 |
| David Wu | West Chester, PA | Infectious Disease | $483,136.42 |
| Warren Joseph | Phoenix, AZ | Primary Podiatric Medicine | $355,947.53 |
| Yoav Golan | Boston, MA | Infectious Disease | $347,718.69 |
| Timothy Franson | Zionsville, IN | Infectious Disease | $301,581.61 |
| Hector Brunet Rodriguez | Shreveport, LA | Infectious Disease | $283,715.82 |
| Christian Sandrock | Sacramento, CA | Internal Medicine | $239,995.45 |
| George Sakoulas | San Diego, CA | Infectious Disease | $223,683.47 |
| Paul Pearigen | San Diego, CA | Emergency Medicine | $207,689.61 |
| Hameed Ali | Temple, TX | Internal Medicine | $197,840.02 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.